[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Pharos University in Alexandria\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":187},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,75,99,119,139,162],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100619392","comparative-analysis-of-2-bone-graft-materials-in-socket-preservation-100619392",false,"NCT07344025","Comparative Analysis of 2 Bone Graft Materials in Socket Preservation","Comparative Analysis of Healing Outcomes Between Two Bone Graft Materials in Socket Preservation Procedure","Inclusion Criteria:\n\n* • Systemically healthy individuals\n\n  * Non-smokers\n  * Age between 21 and 50 years\n  * Indicated for tooth extraction and socket preservation\n  * Good oral hygiene (full-mouth plaque score \\\u003C20%)\n  * Willingness to participate and provide informed consent\n\nExclusion Criteria:\n\n* • Stage III or IV periodontitis\n\n  * Active periodontal or periapical infection\n  * Severely resorbed sockets (buccal bone height \\\u003C5 mm)\n  * Smoking more than 10 cigarettes per day\n  * Pregnancy\n  * Systemic conditions or medications affecting bone metabolism",true,"ALL","21 Years","50 Years",{"count":21,"type":22},18,"ESTIMATED","INTERVENTIONAL",[25],"NA","Socket preservation procedures after tooth extraction have been designed and implemented to maintain the volume of the bone and gingival tissues, which can decrease following the extraction of the teeth. In this clinical trial we will compare clinically and histologically the effectiveness of two distinct bovine bone graft materials; an allograft and a xenograft, in alveolar ridge preservation procedures following tooth extraction .",[28,29,30],"Socket Preservation","Alveolar Ridge Augmentation","Dental Implants",[32,33,34],"Alveolar ridge preservation","Allograft","Bovine xenograft","RECRUITING","2026-01-15",{"date":38,"type":39},"2026-01-20","ACTUAL",{"date":41,"type":22},"2026-01",{"date":43,"type":22},"2026-04",{"name":45,"class":46},"Pharos University in Alexandria","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":16,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":47},"100616658","phase-2-etodolac-nanogel-as-an-adjunct-to-physiotherapy-for-knee-osteoarthritis-100616658","NCT07308470","Etodolac Nanogel as an Adjunct to Physiotherapy for Knee Osteoarthritis","Effect of Etodolac-Loaded Solid Lipid Nanoparticle Gel as an Adjunct to Physiotherapy in Knee Osteoarthritis: A Randomized Clinical Tria","Inclusion Criteria:\n\n* Age between 45 and 60 years.\n\nMild to moderate unilateral knee osteoarthritis (Kellgren-Lawrence grades II-III).\n\nAbility to walk independently without assistive devices.\n\nBody Mass Index (BMI) \\\u003C 30 kg\u002Fm².\n\nNo participation in resistance training in the 3 months prior to enrollment.\n\nReferred by an orthopedic surgeon and diagnosed based on clinical and radiological examination.\n\nExclusion Criteria:\n\n* Severe or bilateral knee osteoarthritis (Kellgren-Lawrence grade IV).\n\nCongenital or acquired inflammatory, rheumatic, or neurological disorders affecting the knee.\n\nRepeated treatment with steroids or secondary knee OA.\n\nHistory of joint replacement surgery in the knee or hip.\n\nCardiovascular or neuromuscular disorders.\n\nDiabetes mellitus.\n\nPsychiatric disorders.","45 Years","60 Years",{"count":58,"type":22},30,[60],"PHASE2","Brief Summary:\n\nKnee osteoarthritis (OA) is a common, disabling condition affecting the weight-bearing knee joint, leading to pain, reduced function, and muscle weakness, particularly of the quadriceps. Strengthening exercises are recommended to improve joint stability, physical function, and slow disease progression. Etodolac, a selective NSAID approved for osteoarthritis, has proven analgesic and anti-inflammatory effects. This study investigates the adjunctive effect of a topical Etodolac-loaded solid lipid nanoparticle gel combined with traditional physiotherapy in patients with knee OA. Thirty patients with mild to moderate unilateral tibiofemoral OA will be randomized into two groups: traditional physiotherapy alone or physiotherapy plus Etodolac gel. Outcomes including pain, knee function, functional performance, quadriceps strength, and proprioception will be assessed at baseline and after four weeks. The study aims to determine whether adding topical Etodolac enhances the benefits of standard physiotherapy in managing knee OA.",[63],"Knee Osteoarthritis",[65],"osteoarthritis-Etodolac","NOT_YET_RECRUITING","2025-12-19",{"date":69,"type":39},"2025-12-29",{"date":71,"type":22},"2026-01-08",{"date":73,"type":22},"2026-03-07",{"name":45,"class":46},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":16,"sex":17,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100606847","hypoxic-vs-aerobic-training-in-chronic-kidney-disease-100606847","NCT07180875","\"Hypoxic vs. Aerobic Training in Chronic Kidney Disease","Simulated Hypoxia Training to Enhance Exercise Tolerance in Stage 3 Chronic Kidney Disease: A Randomized Controlled Trial","IHT-CKD","Inclusion Criteria:Adults (40-65 years) diagnosed with CKD stages 3a,b\n\n* Medically stable and cleared for exercise\n\nExclusion Criteria:\n\n* Uncontrolled hypertension\n* Severe cardiac arrhythmias\n* Recent hospitalization (\\\u003C3 months)\n\ncardiovascular disese unstable","40 Years","65 Years",{"count":86,"type":22},60,[25],"Chronic kidney disease (CKD) leads to poor exercise tolerance, vascular dysfunction, and reduced quality of life. This randomized controlled trial will compare intermittent hypoxic training (IHT) with traditional aerobic training in patients with CKD stages 3-4.\n\nA total of 60 participants aged 40-65 years will be recruited and randomized into three groups. Interventions will last 12 weeks, with three 30-minute supervised sessions per week. Outcome measures include exercise tolerance (6-Minute Walk Test), cardiovascular parameters (blood pressure, heart rate recovery), kidney function (serum creatinine, eGFR), fatigue (Fatigue Severity Scale), and quality of life (KDQOL-36)",[90],"Chronic Kidney Disease (CKD), Stages 3-4 Exercise Tolerance \u002F Functional Capacity Vascular Health \u002F Arterial Stiffness Fatigue in CKD","2025-12-18",{"date":93,"type":39},"2025-12-24",{"date":95,"type":22},"2025-12-09",{"date":97,"type":22},"2026-02-01",{"name":45,"class":46},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":16,"sex":17,"minAge":105,"maxAge":83,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":4},"100609002","methotrexate-iontophoresis-versus-methotrexate-1-gel-on-depigmentation-in-vitiligo-patients-100609002","NCT07208890","Methotrexate Iontophoresis Versus Methotrexate 1% Gel on Depigmentation in Vitiligo Patients","Inclusion Criteria:Clinically diagnosed vitiligo confirmed by a dermatologist.\n\nStable vitiligo for at least 6 months (no new lesions or progression).\n\nAge between 18 and 60 years.\n\nBoth male and female patients.\n\nPresence of localized or segmental vitiligo suitable for topical treatment.\n\nWillingness to avoid other vitiligo treatments (e.g., phototherapy, corticosteroids) during the study period.\n\nAble and willing to provide written informed consent and comply with study procedures -\n\nExclusion Criteria:History of systemic or topical methotrexate use within the past 3 months.\n\nUnstable or rapidly progressive vitiligo during the last 6 months.\n\nPresence of other autoimmune or dermatologic disorders that could interfere with study evaluation (e.g., psoriasis, eczema, lupus).\n\nKnown hypersensitivity or allergy to methotrexate or any gel\u002Fiontophoresis components.\n\nHepatic, renal, or hematologic impairment (abnormal liver function or renal profile).\n\nPregnant or breastfeeding women, or those planning pregnancy during the study period.\n\nUse of phototherapy, corticosteroids, or immunosuppressive therapy within the last 3 months.\n\nMetal implants or pacemakers, which may contraindicate iontophoresis\n\n\\-","18 Years",{"count":58,"type":22},[25],"Vitiligo is a common autoimmune depigmenting disorder characterized by selective destruction of melanocytes. Methotrexate (MTX) has shown potential in stabilizing disease activity and promoting repigmentation; however, systemic administration may cause hepatotoxicity. This pilot study aims to compare the efficacy and safety of methotrexate iontophoresis versus topical methotrexate 1% gel in patients with vitiligo. Thirty patients will be randomly assigned into two equal groups: Group A will receive methotrexate iontophoresis (5-10 mA, 15 min\u002Fsession) for 8 weeks, while Group B will apply methotrexate 1% gel twice daily for 8 weeks. Outcomes will be assessed using the Vitiligo Area and Severity Index (VASI) and the Vitiligo Impact Scale-22 (VIS-22), with liver function monitored monthly",[110],"Vitiligo - Evaluation of Methotrexate Iontophoresis and Topical Methotrexate Gel as Localized Treatment Approache","2025-09-27",{"date":113,"type":39},"2025-10-06",{"date":115,"type":22},"2025-11-10",{"date":117,"type":22},"2026-03-10",{"name":45,"class":46},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":16,"sex":17,"minAge":56,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":136,"leadSponsor":138,"locationsCount":4},"100593989","sarcopenia-and-intervention-physical-therapy-100593989","NCT07013604","Sarcopenia and Intervention Physical Therapy","Effectiveness of Neuromuscular Electrical Stimulation Versus Low-load Resistance Training With Blood Flow Restriction in Elderly Individuals With Sarcopenia","Inclusion Criteria:\n\n* Older age (≥ 60-75 years)\n\nLow muscle strength (e.g., low handgrip strength)\n\nLow muscle mass (e.g., ASM\u002Fheight² below cutoff)\n\nExclusion Criteria:\n\n* heart disese\n* kidny disese\n* autoimune disese\n* cognetive disorder\n* sever form of sarcopenia","75 Years",{"count":86,"type":22},[25],"To evaluate and compare the effectiveness of neuromuscular electrical stimulation (NMES) and low-load resistance training with blood flow restriction (BFR) in improving muscle mass, strength, functional performance, and quality of life in elderly individuals diagnosed with sarcopenia",[131],"Sarcopenia","2025-06-09",{"date":134,"type":39},"2025-06-10",{"date":134,"type":22},{"date":137,"type":22},"2025-09-01",{"name":45,"class":46},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":146,"minAge":83,"maxAge":56,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":47},"100589483","efficacy-of-interval-aerobic-training-versus-laser-puncture-therapy-on-restless-leg-syndrome-in-copd-patient-100589483","NCT06955000","Efficacy of Interval Aerobic Training Versus Laser Puncture Therapy on Restless Leg Syndrome in Copd Patient","Efficacy of Interval Aerobic Training Versus Laser Puncture Therapy on the Severity of Restless Leg Syndrome in Chronic Obstructive Lung Disease Patients","Inclusion Criteria:\n\n* Men with COPD who were between the ages of 40 and 60 and had a BMI between 25.5 and 29.0 were eligible to enroll if they had received a diagnosis of COPD at least two years priorAn intense desire to move the legs is frequently accompanied by unpleasant and uncomfortable leg sensations. Patients usually experience worsening symptoms when they are at rest, sitting, or lying down. Walking and stretching are examples of physical activity that can help reduce these symptoms to some or all of their intensity\n\nExclusion Criteria:\n\n* 1\\) Individuals suffering from acute infections and malignant diseases; 2) Individuals with a history of kidney disease, hiatus hernia, severe gastro-esophageal reflux, and osteoporosis 3) Patients with severe anemia and congestive heart failure 4) Individuals with severe neurological and musculoskeletal conditions.","MALE",{"count":86,"type":22},[25],"DETERMINE HOW TO IMPROVE THE QUALITY OF LIFE FOR PATIENTS WITH COPD BY DECREASING TINTENSITY OF THE RESTLESS SYNDROME",[151],"Chronic Obstructive Pulmonary Disease",[153],"restless leg syndrom,lazer puncture therapy","2025-04-24",{"date":156,"type":39},"2025-05-02",{"date":158,"type":22},"2025-05-25",{"date":160,"type":22},"2025-07-25",{"name":45,"class":46},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":16,"sex":17,"minAge":169,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":23,"phases":173,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":4},"100568229","core-stability-traning-exercises-in-chronic-ankle-instability-in-atheletes-100568229","NCT06678503","Core Stability Traning Exercises in Chronic Ankle Instability in Atheletes","ADDING CORE STABILITY EXERCISES TO CONVENTIONAL PROGRAM IN ATHLETES WITH CHRONIC ANKLE INSTABILITY","Inclusion Criteria:\n\n* Athletes having a history of chronic lateral ankle sprain during the offseason period.\n\n  2\\. Patients aged between 19-30 years, with BMI ranging between (18.5-29.5kg\u002Fm2).\n\n  3\\. Patients having unilateral CAI with the diagnosis to be based on the criteria described by the International Ankle Consortium for enrolling patients of CAI in controlled research (Gribble et al., 2014) as follows:\n  1. A history of at least one significant ankle sprain (the initial sprain must have occurred at least more than 3 months prior to study enrollment, at least one interrupted day of desired physical activity.\n  2. Participants should report at least 2 episodes of giving way and\u002For recurrent sprain and\u002For feelings of instability in the 6 months prior to study enrollment.\n  3. Self-reported ankle instability should be confirmed using a validated ankle instability questionnaire, CAIT\\>24.\n\n     Exclusion Criteria:\n* Those with a history of spine, pelvis, and lower extremity injury, fracture, or surgery.\n\n  2- Those with LBP that required medical or surgical intervention. 3- Those who participated in supervised or unsupervised ankle rehabilitation within 3 months before enrollment in the study.\n\n  4- Having a history of an acute lower extremity injury in the 3 months before the study.\n\n  5\\. Participation in formal rehabilitation in the 3 months before the study. 6. Having a history of lower extremity surgery or fracture that required alignment in the involved limb.\n\n  7\\. Being diagnosed with neurologic dysfunction, such as multiple sclerosis, Parkinson's disease, or head injury.","19 Years","30 Years",{"count":172,"type":22},28,[25],"To study the effect of adding Core stability exercise to the conventional Program of Chronic ankle instability on balance, Functional instability, and Performance in athletes with CAI",[176],"Chronic Ankle Instability and Balance",[178],"Core stability Balance CAI Atheletes","2024-11-10",{"date":181,"type":39},"2024-11-13",{"date":183,"type":22},"2024-12-01",{"date":185,"type":22},"2026-06-01",{"name":45,"class":46},""]